Will Medicare Pay for Wegovy in 2026?

The Short Answer

Depends on your diagnosis and BMI. Medicare Part D pays for Wegovy (semaglutide 2.4 mg) when prescribed to cut cardiovascular risk in beneficiaries with established heart disease and a BMI of 27 or higher. A separate GLP-1 Bridge program pays for Wegovy at a $50 monthly copay for weight loss alone, starting July 1, 2026, for beneficiaries who meet BMI-based criteria. Outside those two pathways, Medicare does not pay for Wegovy.

How Medicare Part D Pays for Wegovy After a Heart Diagnosis

March 2024 marked the turning point: the FDA approved Wegovy to reduce the risk of major adverse cardiovascular events (heart attack, stroke, and cardiovascular death) in overweight or obese adults with established heart disease. CMS confirmed shortly after that Medicare Part D plans could cover Wegovy under that specific indication, because a drug prescribed for cardiovascular risk reduction is not classified as a weight-loss drug under Section 1927(d)(2)(A) of the Social Security Act.

Three conditions must all be documented for Medicare to pay under this pathway:

• Established cardiovascular disease: a prior heart attack (myocardial infarction), a prior stroke, or symptomatic peripheral arterial disease
• A body mass index of 27 or higher (overweight or obese)
• A prescription written specifically for cardiovascular risk reduction, not for weight loss alone

The Medicare GLP-1 Bridge Program, July 2026 Through December 2027

CMS launched the Medicare GLP-1 Bridge on July 1, 2026, an 18-month demonstration that lets eligible Part D enrollees get Wegovy, Foundayo, or the Zepbound KwikPen for a flat $50 monthly copay, no cardiovascular diagnosis required. Three BMI-based tiers define eligibility: a BMI of 35 or higher qualifies with no other diagnosis; a BMI of 30 or higher qualifies with heart failure with preserved ejection fraction, chronic kidney disease stage 3a or higher, or uncontrolled hypertension despite two or more medications; and a BMI of 27 or higher qualifies with prediabetes, a prior heart attack, a prior stroke, or symptomatic peripheral artery disease.

Beneficiaries already diagnosed with type 2 diabetes, obstructive sleep apnea, or MASH (metabolic dysfunction-associated steatohepatitis) do not qualify for the Bridge, because those conditions already open other GLP-1 coverage routes such as Ozempic for diabetes. Roughly 3.8 million Part D members meet the Bridge's BMI-based criteria based on 2023 enrollment counts, according to CMS estimates.

What Wegovy Actually Costs You on Medicare in 2026

Cost splits sharply by pathway. Under the cardiovascular Part D pathway, you pay your plan's standard cost-sharing for a specialty-tier drug, and those payments count toward the 2026 Part D out-of-pocket cap of $2,100, after which your plan covers 100% of the remaining year's costs. Under the GLP-1 Bridge, the flat $50 monthly copay is collected at the pharmacy and does not touch your Part D deductible or your $2,100 cap, which means it never runs out but also never contributes to hitting the cap for your other drugs.

Low-income subsidy (Extra Help) recipients do not get a further discount on the $50 Bridge copay; the flat rate applies to everyone in the program. If you qualify for neither pathway, Wegovy's 2026 list price of $1,349 per month applies in full, and Novo Nordisk's NovoCare savings card explicitly excludes Medicare, Medicaid, and other federal health programs from eligibility.

Medicare Advantage and Wegovy Formularies

Medicare Advantage plans that bundle drug coverage (MA-PD plans) set their own formularies, so whether a specific plan pays for Wegovy depends entirely on that plan's drug list and prior authorization rules. By 2026, most MA-PD plans and standalone Part D plans have added Wegovy to their formularies, tied to the same cardiovascular-risk documentation required under standard Part D, and some also participate in the GLP-1 Bridge. The Medicare Plan Finder tool at medicare.gov lets you search which plans in your area cover Wegovy and at what tier before you enroll.

Why Medicare Still Refuses to Pay for Wegovy in Some Cases

Section 1927(d)(2)(A) of the Social Security Act, added by the Medicare Modernization Act of 2003, prohibits Original Medicare Part D from covering any drug whose primary purpose is weight loss or weight gain. That statute is the reason Medicare historically refused to pay for Wegovy, Saxenda, or other obesity medications, no matter how medically necessary a doctor considered them for a patient's overall health.

The cardiovascular indication and the GLP-1 Bridge are both workarounds, not repeals, of that exclusion: one reclassifies the drug's purpose, the other is a time-limited demonstration authorized separately by CMS. Congress would need to pass new legislation, such as the repeatedly reintroduced Treat and Reduce Obesity Act, to make GLP-1 weight-loss coverage a permanent part of standard Part D.

Confusion sometimes arises because ACA-compliant marketplace plans handle obesity drugs differently. Many state benchmark plans treat obesity screening and treatment as part of the 10 essential health benefits ACA-compliant plans must cover, and marketplace insurers cannot deny that coverage for a preexisting condition. Medicare runs under a separate statute entirely: the weight-loss drug exclusion is a category-level drug exclusion written into Part D law, not a preexisting-condition denial, so ACA marketplace rules on essential health benefits and preexisting conditions have no bearing on what Medicare will pay.

Alternatives If Neither Medicare Pathway Applies to You

Several fallback options exist if you do not have a qualifying cardiovascular diagnosis and your BMI or health history does not fit any GLP-1 Bridge tier. Review the table below before assuming Wegovy is out of reach financially.

Does Medicare Part B pay for Wegovy?

No, never. Part B covers physician-administered drugs given in a clinical setting, not self-injected medications you take at home. Wegovy is a weekly self-injection, so it falls under Part D prescription drug coverage in every case, regardless of diagnosis.

Will Medicare pay for Wegovy for weight loss without heart disease?

Not through standard Part D, because of the Medicare Modernization Act of 2003 weight-loss drug exclusion. Starting July 1, 2026, the GLP-1 Bridge covers Wegovy at $50/month for beneficiaries who meet BMI-based criteria, such as a BMI of 35 or higher, even without a cardiovascular diagnosis.

What heart condition qualifies me for Medicare to pay for Wegovy?

You need established cardiovascular disease, meaning a prior heart attack, a prior stroke, or symptomatic peripheral arterial disease, plus a BMI of 27 or higher. High cholesterol or high blood pressure alone do not qualify you for the cardiovascular Part D pathway.

How much will I pay for Wegovy on Medicare in 2026?

Under the cardiovascular pathway, you pay your plan's standard specialty-tier cost-sharing, which counts toward the $2,100 Part D out-of-pocket cap. Under the GLP-1 Bridge, you pay a flat $50/month that does not count toward that cap. Without either pathway, Wegovy's 2026 list price is $1,349/month.

Does the $50 GLP-1 Bridge copay count toward my Part D deductible or cap?

No. The Bridge operates entirely outside standard Part D benefit structure, so the $50 copay does not reduce your deductible or count toward the $2,100 out-of-pocket cap for 2026. Extra Help (low-income subsidy) does not further reduce the $50 rate.

Will Medicare Advantage plans pay for Wegovy?

Some will, if the plan bundles drug coverage (MA-PD) and lists Wegovy on its formulary, usually with the same cardiovascular-risk documentation Part D requires. Coverage and cost-sharing vary widely by plan, so check the Medicare Plan Finder at medicare.gov before enrolling or switching.

What if I don't qualify for either Medicare pathway?

Options include switching to a Medicare Advantage plan that covers Wegovy during Annual Enrollment (Oct 15 to Dec 7, 2026), checking dual-eligible Medicaid coverage if you qualify by income, or paying cash through a licensed telehealth pharmacy, typically $300 to $600/month. NovoCare's savings card excludes Medicare beneficiaries entirely.

What happens to Medicare's Wegovy coverage after the GLP-1 Bridge ends in December 2027?

CMS planned to hand off to the BALANCE Model demonstration in 2027, but postponed that plan indefinitely in April 2026, extending the Bridge by a year instead. CMS will use Bridge enrollment and cost data to decide whether to continue, replace, or end GLP-1 weight-loss coverage after December 2027.